Tesamorelin: One Approved Population, Many Untested Ones

The short version

Tesamorelin is a synthetic version of growth hormone-releasing hormone, the signal the brain sends to the pituitary gland to release growth hormone. Rather than supplying growth hormone directly, it prompts the body to produce its own in the natural pulsing rhythm the pituitary already uses.

It has one approved use. In 2010 it was approved in the United States to reduce excess abdominal fat in people with HIV-associated lipodystrophy, a redistribution of body fat linked to antiretroviral treatment ^[7]. Inside that population the results are consistent: a meta-analysis of five randomised trials found visceral fat down by a mean of 27.71 cm2, liver fat down by 4.28 percentage points, and lean body mass up by 1.42 kg, all with P<0.001 and without serious adverse events ^[6].

Outside that population, the picture is mostly blank. Not contradicted — unstudied. That distinction does a great deal of work on this page.

What it is

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, written as GHRH(1-44)-NH2, with a trans-3-hexenoic acid group attached to the N-terminus. That single modification is the point of the molecule: it resists cleavage by dipeptidyl peptidase-IV, the enzyme that dismantles native GHRH quickly, so the analogue stays in plasma long enough to act. The free base has the empirical formula C221H366N72O67S, and the clinical product is supplied as the acetate salt.

Its drug class is the growth hormone-releasing hormone receptor agonist. It is a prescription pharmaceutical for one indication and has no approved human use outside it; the labelled indication is HIV-associated lipodystrophy in adults, and every other application — general visceral-fat reduction, anti-ageing use, cognition, non-HIV fatty liver disease — is off-label and investigational.

It is also prohibited in sport. As a GHRH analogue it falls under category S2 of the WADA Prohibited List, covering peptide hormones, growth factors and related substances and mimetics, both in and out of competition.

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor on somatotroph cells in the anterior pituitary. That binding activates the Gs and adenylyl-cyclase pathway, raising cyclic AMP and activating protein kinase A, which drives both the synthesis and the pulsatile secretion of the body's own growth hormone.

Growth hormone in turn stimulates the liver to produce insulin-like growth factor-1. Together, growth hormone and IGF-1 promote lipolysis — the breakdown of stored fat — with a marked preference for visceral adipose tissue, the fat packed around the abdominal organs, rather than the subcutaneous fat under the skin.

The mechanistic distinction that matters is between amplifying an existing rhythm and replacing it. Recombinant growth hormone supplies the hormone from outside and overrides the pituitary's own pattern. Tesamorelin works one step upstream, so the pulses remain the body's own in shape and timing. Its metabolic profile differs from recombinant growth hormone for that reason, and a short study in healthy men showed the difference concretely: two weeks of treatment raised mean overnight growth hormone by 0.5 ug/L (P=0.004) and IGF-1 by 181 ug/L (P<0.0001), while fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) were unchanged ^[9].

What the research shows

Pooled randomised evidence. A 2026 meta-analysis of five randomised controlled trials in HIV-associated lipodystrophy reported a reduction in visceral adipose tissue of 27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), a fall in trunk fat of 1.18 kg, a reduction in hepatic fat fraction of 4.28 percentage points, and an increase in lean body mass of 1.42 kg, all at P<0.001, with no serious adverse events reported ^[6].

A single controlled trial in detail. A six-month randomised trial published in JAMA enrolled 50 antiretroviral-treated adults with HIV — 28 assigned tesamorelin, 22 placebo. Participants in the treatment arm received 2 mg per day, and the treatment effect on visceral fat was -42 cm2 (P=0.005), with hepatic lipid-to-water percentage falling by a net 2.9 percentage points (P=0.003) ^[8].

Endocrine effect without measurable glucose cost. In 13 healthy men given 2 mg per day for two weeks, mean overnight growth hormone rose by 0.5 ug/L (P=0.004) and IGF-1 by 181 ug/L (P<0.0001), while neither fasting glucose (P=0.93) nor insulin-stimulated glucose uptake (P=0.61) changed significantly ^[9].

The long view, and what stopping does. In the 52-week programme — 273 participants on 2 mg per day against 137 on placebo — the reduction in visceral adipose tissue was sustained at -18% over the full year (P<0.001 versus baseline) ^[10]. Visceral fat reaccumulated once treatment stopped, and changes in glucose parameters across the 52 weeks were not clinically significant ^[10].

Liver safety. The NIH LiverTox monograph, which grades drugs on their likelihood of causing clinically apparent liver injury, assigns tesamorelin a likelihood score of E — unlikely — noting no reported attributable cases of liver injury and no de novo serum-enzyme elevations in the trials ^[7].

Reported effects, cautions & safety

This desk carries no community-report set for tesamorelin, and none is invented here. Unlike the other two compounds on this site, it has never had a large informal user population writing up its effects, which is itself informative: it is an expensive, injection-only prescription product with one narrow indication, so the people using it are largely people prescribed it. Where a section like this would normally summarise what users say, there is nothing to summarise, and the trial record has to carry the whole weight.

That record is reassuring as far as it goes. The pooled analysis of five randomised trials reported its body-composition results without serious adverse events ^[6]. The 52-week programme found changes in glucose parameters that were not clinically significant across the year ^[10], and the two-week study in healthy men found insulin-stimulated glucose uptake preserved ^[9]. On the liver, the LiverTox monograph records no attributable cases of clinically apparent injury and no de novo enzyme elevations in trials, giving the lowest likelihood grade ^[7].

The cautions that attach to it come from its mechanism and its regulatory position rather than from an adverse-event tally. Because it works by raising growth hormone, it also raises IGF-1 — a growth factor — and while the trials showed no excess malignancy signal across 52 weeks ^[10], long-term oncological safety data are limited and active malignancy is a labelled contraindication. Modest disturbance of glucose can occur, which is why monitoring is discussed for people with prediabetes or dysglycemia even though the dedicated type 2 diabetes trial found no significant change in HbA1c. The benefit is contingent on continued treatment: visceral fat returns within weeks of stopping ^[10]. And material sold as research-grade tesamorelin for laboratory use lacks the purity and potency oversight of the approved product entirely, so none of the results above describe it.

Where it sits on the open-question map

Tesamorelin is the clearest illustration on this site of a compound whose evidence is strong and narrow at the same time.

The population question. Every pivotal trial enrolled antiretroviral-treated adults with HIV-associated lipodystrophy ^[6][8][10]. Whether the same visceral-fat effect appears in people without HIV is mechanistically plausible — the pituitary works the same way — but it has not been established by large randomised trials, and plausibility is not evidence.

The permanence question. The 52-week data show sustained visceral-fat reduction while treatment continues and reaccumulation after it stops ^[10]. That reframes it as an ongoing intervention rather than a correction, and it raises a question no trial answers: what an indefinite course looks like over years.

The oncological horizon. Raising IGF-1 raises a theoretical concern that a 52-week follow-up is too short to resolve in either direction. The absence of a signal over a year is not the presence of long-term safety data.

The cognition question is genuinely mixed. The wider discussion of tesamorelin includes a trial in a non-HIV ageing population reporting a benefit in executive function and a 2025 trial in HIV cognition that did not show significant neurocognitive improvement over standard care. Neither is among the sources listed on this desk, and nothing here reconciles them.

The access question. High cost and injection-only administration limit its use, which shapes who appears in the literature at all and leaves the informal evidence base sparse.

What remains, in every case, is a judgement about whether a particular person resembles the trial population closely enough for the result to transfer. That is a clinical question by construction — it depends on a history this desk has no access to.